BK virus-specific T cell therapy - Cellevolve
Latest Information Update: 20 Jan 2023
At a glance
- Originator Cellevolve
- Class Gene therapies; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Kidney disorders
Most Recent Events
- 08 Dec 2022 Phase-I/II clinical trials in Kidney disorders in USA (IV) prior to December 2022 (Cellevolve pipeline, December 2022)
- 01 Dec 2021 Cellevolve and QIMR Berghofer Medical Research Institute enters into research and development agreement for the development of BK-virus specific cell therapy